Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Di | Pfizer und BioNTech: Gegenwind aus den USA - die Details | 979 | Der Aktionär | Die US-Arzneimittelbehörde FDA erwägt, die Notfallzulassung des Covid-Impfstoffs von Pfizer und dem Partner BioNTech für gesunde Kinder unter fünf Jahren zu widerrufen. Dies bestätigte der US-Pharmakonzern... ► Artikel lesen | |
Di | Autolus Therapeutics plc: Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates | 450 | GlobeNewswire (Europe) | Company reports Q2 2025 AUCATZYL® net product revenue of $20.9 million and $29.9 for the first six months of 2025Company recently received conditional marketing authorization from U.K. Medicines and... ► Artikel lesen | |
Di | XFRA IM8N: WIEDERAUFNAHME/RESUMPTION | 289 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
Di | Climb Bio, Inc.: Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates | 248 | GlobeNewswire (Europe) | Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of Budoprutug in Primary Membranous Nephropathy (pMN) Expected to Initiate in... ► Artikel lesen | |
Di | Centessa Pharmaceuticals plc: Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2025 | 241 | GlobeNewswire (Europe) | Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year
ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type... ► Artikel lesen | |
Di | XFRA IM8N: AUSSETZUNG/SUSPENSION | 223 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILINSMED INC. DL-... ► Artikel lesen | |
Di | Amphastar Pharmaceuticals, Inc.: Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd. | 209 | ACCESS Newswire | Agreement strengthens proprietary peptide pipeline targeting high-value oncology and ophthalmology indications RANCHO CUCAMONGA, CA / ACCESS Newswire / August 12, 2025 / Amphastar Pharmaceuticals, Inc.... ► Artikel lesen | |
Di | SIGA Technologies - A solid quarter for topline growth | 175 | Edison Investment Research | Q225 was a strong quarter for SIGA, supported by material topline traction, with deliveries of $79m of oral and IV TPOXX to the US strategic national stockpile (SNS), fully servicing the order book... ► Artikel lesen | |
Di | Insmed Incorporated: FDA Approves BRINSUPRI (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease | 173 | PR Newswire | - Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage... ► Artikel lesen | |
Di | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update | 106 | GlobeNewswire (Europe) | Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from... ► Artikel lesen | |
Di | Anavex Life Sciences Corp.: Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update | 84 | GlobeNewswire (Europe) | Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical... ► Artikel lesen |
Unternehmen / Aktien | Kurs | Dividende 12M | Div.-Rendite | Erw. Dividende | Erw. Ex.-Datum | |
---|---|---|---|---|---|---|
VIATRIS | 8,608 | 0,41 | +4,76 % | 0,12 | 22.08.2025 | |
AMGEN | 243,20 | 8,08 | +3,32 % | 2,38 | 22.08.2025 | |
GILEAD SCIENCES | 102,04 | 2,68 | +2,63 % | 0,79 | 15.09.2025 | |
ROYALTY PHARMA | 30,980 | 0,75 | +2,42 % | 0,22 | 15.08.2025 | |
ASTRAZENECA PLC ADR | 65,00 | 1,35 | +2,08 % | 0,52 | 08.08.2025 | |
GRIFOLS | 12,680 | 0,15 | +1,18 % | 0,15 | 11.08.2025 | |
REGENERON PHARMACEUTICALS | 475,80 | 2,27 | +0,48 % | 0,88 | 18.08.2025 | |
IONIS PHARMACEUTICALS | 35,520 | 0,00 | 0,00 % | |||
BIOGEN | 110,95 | 0,00 | 0,00 % | |||
ALTIMMUNE | 3,167 | 0,00 | 0,00 % |
Aktien WKN | Akt. Kurs Vortag | +/- % | Zeit | ||
---|---|---|---|---|---|
10X GENOMICS INC A2PPQJ Tradegate | 10,905 10,615 | -0,070 -0,64 % | 12.08. | ||
4D MOLECULAR THERAPEUTICS INC A2PS5P NASDAQ | 6,145 5,530 | 0,000 0,00 % | 12.08. | ||
89BIO INC A2PUP8 NASDAQ | 9,045 9,190 | 0,000 0,00 % | 12.08. | ||
ABCELLERA BIOLOGICS INC A2QKXS Tradegate | 3,623 3,653 | -0,030 -0,82 % | 10:04 | ||
ABSCI CORPORATION A3CVW3 NASDAQ | 2,975 2,850 | 0,000 0,00 % | 12.08. | ||
AC IMMUNE SA A2AR5F Tradegate | 1,876 1,852 | +0,024 +1,30 % | 09:57 | ||
ACADIA PHARMACEUTICALS INC 603035 Tradegate | 22,010 21,400 | +0,210 +0,96 % | 12.08. | ||
ACRIVON THERAPEUTICS INC A3DXE7 NASDAQ | 1,260 1,220 | +0,030 +2,44 % | 12.08. | ||
ADAPTIVE BIOTECHNOLOGIES CORPORATION A2PLR5 Tradegate | 11,015 10,475 | +0,175 +1,61 % | 12.08. | ||
ADMA BIOLOGICS INC A12FAG NASDAQ | 16,760 16,390 | 0,000 0,00 % | 12.08. |